cessation of smokeless tobacco and mortality post-MI

circulation just published article from sweden on profound effect of cessation of smokeless tobacco on post-MI mortality (see smokeless tobacco cessation dec MI circ 2014 in dropbox, or DOI: 10.1161/CIRCULATIONAHA.113.007252). they assessed all patients who were <75 years old admitted to CCUs for MI between 2005-9 (the database included the vast majority of swedish hospitals). they followed patients for 2.1 years post-MI to assess the relative difference in mortality in the 675 who quit snus ( their form of oral snuff) vs 1799 who continued using. results:

    --83 people died in the 2.1 years of follow-up
    --mortality rate in those who quit snus was 9.7/1000 person-years; mortality rate in those who continued snus was 18.7/1000 person-years
    --adjusted for age and gender, the mortality rate HR was 0.51 (0.29-0.91) for quitters; in multivariable-adjusted model, HR was 0.57 (0.32-1.02)
    --these results were remarkably similar to those who quit smoking, with HR 0.54 (0.42-0.69)

sweden has the highest prevalence of snuff use, though the overall snuff market is highest in the US (1.7 billion cans/yr, and growing at 5%/yr). nicotine levels in swedish snuff is similar to US (though they do pasteurize it and lower the carcinogenic nitrosamines). snuff (and snus) is associated with endothelial dysfunction, and increased blood pressure, heart rate and adrenaline, and perhaps increased risk of heart failure. animal studies suggest increase in ventricular arrhythmias post-MI.  there are caveats to the study: all patients were recruited 2 months post-MI (ie, we do not have data on nonsurvivors, though prior data suggest that snus users have a higher MI mortality), many patients used both snus and smoked (though above controlled mathematically for smoking status, but the actual % of patients who never smoked but used snus was small), this was not an intervention study but a prospective observational one, and those who continued to use snus were less likely to participate in a cardiac rehab program. nonetheless, this study highlights the potential cardiotoxicity and mortality associated with smokeless tobacco and the potential to halve the risk of subsequent mortality through cessation and reinforces the importance for us to be as aggressive in helping patients quit smokeless tobacco as we are with smokers.

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more